Combination of haploidentical haematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: a report of 146 cases

Liu, Limin; Zhang, Yanming; Jiao, Wenjing; Zhou, Huifen; Wang, Hongtao; Qiu, Huiying; Tang, Xiaowen; Han, Yue; Fu, Chengcheng; Jin, Zhengming; Chen, Suning; Sun, Aining; Miao, Miao; Wu, Depei

doi:10.1038/s41409-020-0874-9

Cited by 15 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a total of 19.4%-92% of these patients experienced CMV reactivation after combination of haploSCT with UCB or MSCs (24)(25)(26)(27)(28). There was no statistical significance in the incidence of CMV viremia in terms of haplo-cord SCT vs HLA-matched donor SCT (MD-SCT) or haplo-cord SCT vs haploSCT (24)(25)(26).…”

Section: Incidence Of Cytomegalovirus Infection After Haplosctmentioning

confidence: 97%

“…The median time to the onset of CMV DNAemia in the haploSCT group was 33 days (range, 10-159 days) with the 1-year cumulative incidence of CMV disease at 7.9% (95% CI, 3.6-14.3%) (29). In addition, a total of 19.4%-92% of these patients experienced CMV reactivation after combination of haploSCT with UCB or MSCs (24)(25)(26)(27)(28). There was no statistical significance in the incidence of CMV viremia in terms of haplo-cord SCT vs HLA-matched donor SCT (MD-SCT) or haplo-cord SCT vs haploSCT (24)(25)(26).…”

Section: Incidence Of Cytomegalovirus Infection After Haplosctmentioning

confidence: 99%

“…Using a similar protocol, several transplant centers have reported promising results for unmanipulated haploidentical peripheral blood stem cell transplantation (PBSCT) (22,23) or cotransplantation of unrelated cord blood (UCB) (24)(25)(26) or mesenchymal stem cells (MSCs) (27,28). The 1-year cumulative incidence of CMV DNAemia in patients with hematologic malignancies was 23.5-41.7% in the matched sibling donor (MSD)-SCT group versus 62.1-81.0% in the haploSCT group with peripheral blood stem cells (PBSCs) (29,30).…”

Section: Incidence Of Cytomegalovirus Infection After Haplosctmentioning

confidence: 99%

See 2 more Smart Citations

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update

et al. 2021

View full text Add to dashboard Cite

Haploidentical stem cell transplantation (haploSCT) has advanced to a common procedure for treating patients with hematological malignancies and immunodeficiency diseases. However, cure is seriously hampered by cytomegalovirus (CMV) infections and delayed immune reconstitution for the majority of haploidentical transplant recipients compared to HLA-matched stem cell transplantation. Three major approaches, including in vivo T-cell depletion (TCD) using antithymocyte globulin for haploSCT (in vivo TCD-haploSCT), ex vivo TCD using CD34 + positive selection for haploSCT (ex vivo TCD-haploSCT), and T-cell replete haploSCT using posttransplant cyclophosphamide (PTCy-haploSCT), are currently used worldwide. We provide an update on CMV infection and CMV-specific immune recovery in this fast-evolving field. The progress made in cellular immunotherapy of CMV infection after haploSCT is also addressed. Groundwork has been prepared for the creation of personalized avenues to enhance immune reconstitution and decrease the incidence of CMV infection after haploSCT.

show abstract

Section: Incidence Of Cytomegalovirus Infection After Haplosctmentioning

confidence: 97%

Section: Incidence Of Cytomegalovirus Infection After Haplosctmentioning

confidence: 99%

Section: Incidence Of Cytomegalovirus Infection After Haplosctmentioning

confidence: 99%

See 1 more Smart Citation

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update

et al. 2021

View full text Add to dashboard Cite

show abstract

“…When co-transplantation of haplo-HSCT and the donor-derived UC-MSCs for SAA patients, it had fewer complications, accelerated hematopoietic reconstitution, reduced incidence of severe GVHD and transplant-related mortality ( Wu et al, 2014 ; Liu et al, 2020b ). In addition, several studies have shown that co-transplantation of haplo-HSCT and UC-MSCs from third-party donors has yielded favorable results for SAA patients: overall survival and GVHD-free are improved, which demonstrate a feasible choice for SAA patients without matched donors in improving donor engraftment and reducing severe GVHD ( Wu et al, 2011 ; Liu et al, 2020b ). Clinical data from co-transplantation of unrelated donor peripheral blood stem cell (PBSCs) and UC-MSCs for young patients with refractory SAA also showed similar results ( Fu et al, 2013 ).…”

Section: Application Of Uc-mscs In Hematologic Diseasesmentioning

confidence: 99%

Biological Characteristics of Umbilical Cord Mesenchymal Stem Cells and Its Therapeutic Potential for Hematological Disorders

Shang

Guan

Zhou

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Umbilical cord mesenchymal stem cells (UC-MSCs) are a class of multifunctional stem cells isolated and cultured from umbilical cord. They possessed the characteristics of highly self-renewal, multi-directional differentiation potential and low immunogenicity. Its application in the field of tissue engineering and gene therapy has achieved a series of results. Recent studies have confirmed their characteristics of inhibiting tumor cell proliferation and migration to nest of cancer. The ability of UC-MSCs to support hematopoietic microenvironment and suppress immune system suggests that they can improve engraftment after hematopoietic stem cell transplantation, which shows great potential in treatment of hematologic diseases. This review will focus on the latest advances in biological characteristics and mechanism of UC-MSCs in treatment of hematological diseases.

show abstract

“…13 Cyclosporin A, short-term methotrexate, and mycophenolate mofetil were used for graft-versus-host disease (GvHD) prophylaxis. 14 Moreover, Anti-Thymocyte Globulin (ATG, Genzyme, Cambridge, MA, USA) was also administrated in vivo at 2.5 mg/kg on days -5 to -2 for preventing GvHD after haploidentical allo-HSCT.…”

Section: Treatment Protocolsmentioning

confidence: 99%

Genetic Profile and Clinical Implications of PDGFRB Fusion in Adult B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis

Xu¹,

Bao²,

Liu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background:To investigate the pathogenesis, genetic changes, treatment and prognosis of adult B-cell acute lymphoblastic leukemia (B-ALL) with platelet-derived growth factor receptor B (PDGFRB) fusion. Method：Clinical characteristics, treatment process and prognosis of 7 adult B-ALL patients with PDGFRB fusion were presented respectively, and the PDGFRB fusion was confirmed by fluorescence in situ hybridization, RNA sequencing and Polymerase Chain Reaction. Results: 7 adult B-ALL patients with PDGFRB fusion were presented respectively. There were 5 males and 2 females, with a median age of 21 (range, 17-39) years and a median white blood cell count of 7.85 (range, 2.30-111.25) ×10^9/L. The fusion partners were EBF1, SMIM3 and TERF2. Three of 7 cases received tyrosine kinase inhibitor (TKI) targeted therapy, and 4 of 7 cases received chimeric antigen receptor T -cell (CAR-T) therapy. A total of 6 (85.71%) cases underwent haploid hematopoietic stem cell transplantation (Haplo-HSCT). Overall response rate was 71.43% (4/7), and the common adverse reactions during induction were febrile neutropenia and nausea. Seventy-five percent (3/4) and 100% (6/6) of patients were minimal residual disease negative after CAR-T and Haplo-HSCT. To the last follow-up, 2 of 7 cases relapsed in 2 and 7 months after remission, respectively, and the estimated 36 months of Event-free survival and Overall survival was 75.0% and 66.7%.Conclusions: intensive therapy combined with CAR-T or TKI is needed to achieve deep remission, and sequential Haplo-HSCT may improve the prognosis of adult B-ALL with PDGFRB fusion.

show abstract

Combination of haploidentical haematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: a report of 146 cases

Cited by 15 publications

References 33 publications

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update

Biological Characteristics of Umbilical Cord Mesenchymal Stem Cells and Its Therapeutic Potential for Hematological Disorders

Genetic Profile and Clinical Implications of PDGFRB Fusion in Adult B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis

Contact Info

Product

Resources

About